HypoPet AG, a spin-off biotechnology company of the University of Zurich, is aspiring to preserve and strengthen the timeless and loving bond that exists between humans and their beloved animal companions. Similar to humans, domestic animals also suffer from chronic diseases such as allergy or inflammation, but state of the art therapies specially designed for pets are often not available. HypoPet is addressing this deficiency in the care of our pets by developing a precision, cutting-edge vaccine technology that instructs the animal's body to make its own antibodies which are capable of ameliorating chronic diseases such as allergy, inflammation, pain and cancer. HypoPet's vaccine technology has the potential to transform the latest and most effective innovations in human medicines into a new, efficacious and affordable class of veterinary medicine. Specifically, the remarkable advances achieved in the treatment of chronic human diseases by the use of monoclonal antibodies may now be made available to pets by the use of our pet-specific vaccines. HypoPet's patented vaccine platform is being used to develop a broad pipeline of drugs that address major unmet needs in key areas of veterinary medicine such as allergy, inflammation, pain, nervous system disorder and cancer. HypoPet wants to improve the well-being and quality-of-life of pets and their owners.
NEWS - Zürich Switzerland 17th of April 2019Key preclinical data for HypoPet’s cat allergy vaccine (HypoCat™ / VC001) published in leading allergy journal.
Zürich Switzerland 17th of April 2019 – HypoPet AG today announced the publication of important preclinical data for their cat allergy vaccine, HypoCat™. The data were published online 17th of April 2019 in an article entitled “Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. “in the Journal of Allergy and Clinical Immunology.
The published work, led by HypoPet’s Zurich-based research team (in collaboration with researchers from the Latvian Biomedical Research and Study Centre Riga, Vetsuisse Faculty University of Zurich and the Functional Genomics Centre Zürich, University of Zürich), showed that HypoPet’s virus-like particle vaccine targeting the major feline allergen (i.e. Fel d 1) to which humans are allergic, successfully induced Fel d 1 binding antibodies in cats and that these antibodies neutralized the allergen. Furthermore, the HypoCat™ vaccine was reported to be well tolerated without any overt toxicity. The data described in the paper were generated from 4 separate studies involving a total of 54 cats.
Dr Gary Jennings, CEO of HypoPet AG, commented, “We are very pleased to publish this data which shows our HypoCat™ vaccine is able to produce high levels of antibodies in cats and that these antibodies can bind and neutralize the Fel d 1 allergen produced by the animals. This work was a key step in the milestone driven development of HypoCat™, the lead project in our product pipeline. Moreover, our development partner Benchmark Holdings recently announced successful completion of other key safety and efficacy trials and transfer of the HypoCat manufacture process to GMP. Consequently, we are pressing ahead with registration studies and discussions with European and U.S regulators with the hope of bringing this much-needed product to the market”
Go to dowload the press release
HypoPet scientists publish data showing proof-of-principle achieved for a vaccine targeting osteoarthritic pain
Zürich Switzerland 19th of March 2019 – HypoPet AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals. The data were published online 12th of March 2019 in an article entitled “Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis” in the Annals of the Rheumatic Diseases
A research collaboration between Martin Bachmann’s research groups at the Jenner Institute University of Oxford and University of Bern and academic researchers from the Kennedy Institute of Rheumatology University of Oxford and Latvian Biomedical Research and Study Center demonstrated the succesfull development and testing of a VLP-based vaccine with the potential to treat chronic pain caused by osteoarthritis. The virus-like particle vaccine triggers the immune system to produce antibodies that block the activity of nerve growth factor – a key mediator of inflammatory and chronic pain.
Professor Martin Bachmann CSO of HypoPet AG commented, “I am happy to see the vaccine platform perform so well, and look forward to seeing the vaccine enter clinical testing in companion animals in the near future”.
9th January 2019: HypoPet to present at Animal Health Investment Forum London
HypoPet AG today announced that it has been selected as a finalist to present at the prestigious Animal Health Investment Europe Forum in February 2019. The Animal Health Innovation showcase provides an opportunity for the most exciting and innovative emerging animal health companies, selected by committee, to present their breakthrough innovations and business to investors and industry professionals.
Company founder and CSO Martin Bachmann will give HypoPet’s 10 min presentation in London, Aldersgate on the 26th of February.
Proof of concept data for HypoPet’s virus-like particle vaccine for treating canine atopic dermatitis published in leading allergy journal.
Zürich Switzerland 11th of April 2018 – HypoPet AG today announced the publication of Proof of Concept data for a vaccine for treating canine atopic dermatitis (CAD) in the renowned Journal of Allergy and Clinical Immunology. The data were published online 4th of April 2018 in an article entitled “Vaccination against IL-31 for the treatment of atopic dermatitis in dogs”.